# A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

> **NCT06225635** · PHASE1 · COMPLETED · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Hyperlipidemias

## Interventions

- **DRUG:** Ezerosu(monolayer tablet)
- **DRUG:** Ezerosu(double layer tablet)

## Key facts

- **NCT ID:** NCT06225635
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2022-03-07
- **Final completion:** 2022-03-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06225635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06225635, "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06225635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*